Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives.
Expert Rev Neurother
; 20(6): 627-641, 2020 06.
Article
em En
| MEDLINE
| ID: mdl-32434430
ABSTRACT
INTRODUCTION:
Calcitonin Gene-Related Peptide (CGRP) has gradually emerged as a suitable therapeutic target to treat migraine. Considering the social and economic burden of migraine, it is fundamental to optimize the disease management with efficacious and safe treatments. In this scenario, drugs targeting GCRP, monoclonal antibodies (MoAbs) and gepants, represent new therapeutic strategies. AREAS COVERED In the present work, the authors aim at appraising the main insights and implications of treatments targeting CGRP by reviewing pathophysiology and clinical information. EXPERT OPINION Anti-CGRP MoAbs are the first migraine-specific preventive treatments representing a suitable option especially for difficult-to-treat patients. They can be safely administered for long periods even in association with preventatives acting on different targets. Gepants are a safe alternative to triptans for the acute management of migraine and are currently being tested for prevention, thus representing the first transitional molecules for disease therapy. In the future, it might be possible to adapt the treatment according to patients' characteristics and disease phenotype even combining the two treatments targeting the CGRP pathway.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antagonistas do Receptor do Peptídeo Relacionado ao Gene de Calcitonina
/
Transtornos de Enxaqueca
/
Anticorpos Monoclonais
Limite:
Humans
Idioma:
En
Revista:
Expert Rev Neurother
Assunto da revista:
NEUROLOGIA
/
TERAPEUTICA
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Itália